Evidence map›Paper›PMID 36082118›Full record

ArticleFrontiers in cardiovascular medicine2022

MAGI1 inhibits interferon signaling to promote influenza A infection.

Yin Wang, Jun-Ichi Abe, Khanh M Chau, Yongxing Wang, Hang Thi Vu, Loka Reddy Velatooru, Fahad Gulraiz, Masaki Imanishi, Venkata S K Samanthapudi, Minh T H Nguyen and 10 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Yin WangDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jun-Ichi AbeDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Khanh M ChauDepartment of Cardiovascular Sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, TX, United States.
Yongxing WangDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Hang Thi VuDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Loka Reddy VelatooruDepartment of Cardiovascular Sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, TX, United States.
Fahad GulraizDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Masaki ImanishiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Venkata S K SamanthapudiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Minh T H NguyenDepartment of Cardiovascular Sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, TX, United States.
Kyung Ae KoDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Ling-Ling LeeDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Tamlyn N ThomasDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Elizabeth A Olmsted-DavisDepartment of Cardiovascular Sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, TX, United States.
Sivareddy KotlaDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Keigi FujiwaraDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
John P CookeDepartment of Cardiovascular Sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, TX, United States.
Di ZhaoDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Scott E EvansDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Nhat-Tu LeDepartment of Cardiovascular Sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute, Houston, TX, United States.
The University of Texas MD Anderson Cancer Center · USHouston Methodist · US

Funding

Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumoniaR35HL144805 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2019 to 2025
$6.2M
Reversal of Heart Failure: Role of Vascular RecoveryR01HL148338 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, KAIFU, COOKE, JOHN P · 2020 to 2023
$2.8M
A Novel Role for MAGI1 in regulating non-canonical LATS signaling and atherosclerotic plaque formationR01HL134740 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LE, NHAT-TU · 2017 to 2021
$2.0M
Epigenetic reprogramming to generate novel chondro-osseous stem cells for bone tissue engineeringR21AR077783 · NIAMS · BAYLOR COLLEGE OF MEDICINE · PI DAVIS, ALAN ROBERT, DAVIS, ELIZABETH ANN · 2020 to 2021
$382k
NHLBI NIH HHS R01 HL134740NHLBI NIH HHS R01 HL148338NHLBI NIH HHS R35 HL144805NIAMS NIH HHS R21 AR077783
6 · The paper itself

Abstract

We have shown that membrane-associated guanylate kinase with inverted domain structure-1 (MAGI1), a scaffold protein with six PSD95/DiscLarge/ZO-1 (PDZ) domains, is involved in the regulation of endothelial cell (EC) activation and atherogenesis in mice. In addition to causing acute respiratory disease, influenza A virus (IAV) infection plays an important role in atherogenesis and triggers acute coronary syndromes and fatal myocardial infarction. Therefore, the aim of this study is to investigate the function and regulation of MAGI1 in IAV-induced EC activation. Whereas, EC infection by IAV increases MAGI1 expression, MAGI1 depletion suppresses IAV infection, suggesting that the induction of MAGI1 may promote IAV infection. Treatment of ECs with oxidized low-density lipoprotein (OxLDL) increases MAGI1 expression and IAV infection, suggesting that MAGI1 is part of the mechanistic link between serum lipid levels and patient prognosis following IAV infection. Our microarray studies suggest that MAGI1-depleted ECs increase protein expression and signaling networks involve in interferon (IFN) production. Specifically, infection of MAGI1-null ECs with IAV upregulates expression of signal transducer and activator of transcription 1 (STAT1), interferon b1 (IFNb1), myxovirus resistance protein 1 (MX1) and 2'-5'-oligoadenylate synthetase 2 (OAS2), and activate STAT5. By contrast, MAGI1 overexpression inhibits

Indexed as

EC inflammationIAVinterferon signalingIRF3MAGI1MX1

Identifiers

PMID36082118
PMCPMC9445416
OpenAlexW4292835363

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.